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Abstract 
The recurrent 9p24.1 aberrations in lymphoid malignancies potentially involving four cancer-related and 
druggable genes (JAK2, CD274/PDL1, PDCD1LG2/PDL2 and KDM4C/JMJD2Cl) are incompletely 
characterized. To gain more insight into the anatomy of these abnormalities, at first we studied 9p24.1 
alterations in 18 leukemia/lymphoma cases using cytogenetic and molecular techniques. The aberrations 
comprised structural (nine cases) and numerical (nine cases) alterations. The former lesions were 
heterogeneous but shared a common breakpoint region of 200 kb downstream of JAK2. The 
rearrangements predominantly targeted the PDL locus. We have identified five potential partner genes of 
PDL1/2: PHACTR4/1p34, N4BP2/4p14, EEF1A1/6q13, JAK2/9p24.1 and IGL/22q11. Interestingly, the 
cryptic JAK2-PDL1 rearrangement was generated by a microdeletion spanning the 3’JAK2-5’PDL1 region. 
JAK2 was additionally involved in a cytogenetically cryptic IGH-mediated t(9;14)(p24.1;q32) found in two 
patients. This rare but likely underestimated rearrangement highlights the essential role of JAK2 in B-cell 
neoplasms. Cases with amplification of 9p24.1 were diagnosed as primary mediastinal B-cell lymphoma 
(five cases) and T-cell lymphoma (four cases). The smallest amplified 9p24.1 region was restricted to the 
JAK2-PDL1/2-RANBP6 interval. In the next step, we screened 200 cases of classical Hodgkin lymphoma 
by interphase FISH and identified PDL1/2 rearrangement (CIITA- and IGH-negative) in four cases (2%), 
what is a novel finding. Forty (25%) cases revealed high level amplification of 9p24.1, including four cases 
with a selective amplification of PDL1/2. Altogether, the majority of 9p24.1 rearrangements occurring in 
lymphoid malignancies seem to target the programmed death-1 ligands, what potentiates the therapeutic 
activity of PD-1 blockade in these tumors.   
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INTRODUCTION 
Genomic alterations of the 9p24.1 region, recurrent in hematological malignancies, have drawn a 
longstanding attention. The involved interval contains four cancer-related genes, JAK2, CD274/PDL1, 
PDCD1LG2/PDL2 and KDM4C/JMJD2Cl, all druggable targets for precision therapy (Sharma et al., 2011; 
Hao et al., 2014; Chin & Han, 2015). In addition to the 9p24.1 amplification hallmarking primary 
mediastinal B-cell lymphoma (PMBCL) and classic Hodgkin lymphoma (cHL) (Joos et al., 2000; Bentz et 
al., 2001; Meier et al., 2009; Green et al., 2010), all four genes are targeted by various 
leukemia/lymphoma-related rearrangements. The best known targeted gene, JAK2, encodes a non-
receptor tyrosine kinase which plays a key role in the JAK-STAT signaling pathway downstream of 
several cytokine receptors (Ghoreschi et al., 2009). JAK2 is frequently activated by mutations and 
chromosomal translocations in myeloproliferative disorders (Vainchenker et al., 2008; Skoda et al., 2015) 
and involved in recurrent rearrangements, including SEC31A-JAK2 in cHL (Van Roosbroeck et al., 2011). 
CD274 and PDCD1LG2 (further referred to as PDL1 and PDL2, respectively) are coding for the 
programmed death-1 (PD-1) ligands, which act as negative regulators of anti-tumor immunity by binding 
their cognate receptor, PD-1, on cytotoxic T-cells, and which induce T-cell “exhaustion” (Blank & 
Mackensen, 2007; Keir et al., 2008; Zou & Chen, 2008; Andorsky et al., 2011). Rearrangements of the 
PDL loci were recently detected in 20% of PMBCL and in sporadic cases of primary testicular diffuse 
large B-cell lymphoma (DLBCL), primary central nervous system lymphoma and two HL-derived cell lines 
(Steidl et al., 2011; Twa et al., 2014; Berghoff et al., 2014; Twa et al., 2015). Thus far, three genes, CIITA, 
IGH and NRG1, were identified as PDL-fusion partners by high-throughput sequencing (Steidl et al., 
2011; Twa et al., 2014; Twa et al., 2015; Twa & Steidl, 2015). KDM4C encodes a lysine-specific 
demethylase, which regulates histone methylation dynamics and plays critical roles in modulating 
chromatin architecture, gene transcription, and cellular differentiation (Berry & Janknecht, 2013). KDM4C  
is involved in a rare IGH-mediated translocation in mucosa-associated lymphoid tissue (MALT) lymphoma 
(Vinatzer et al., 2008). Noteworthy, the 9p24.1 amplification frequently observed in PMBCL and cHL, 
does not target a single gene, but affects at least 10 protein-coding genes, among others JAK2, PDL1, 
PDL2 and KDM4C, located within the ~3.5 Mb commonly amplified interval (Rui et al., 2010). Following 
the concept of cooperative oncogenic effects of multiple genes within amplicons, the authors provided 
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evidence that JAK2 and KDM4C cooperatively modify the epigenome of the amp(9p24.1)-positive 
lymphomas and, consequently, enhance proliferation and survival of neoplastic cells (Rui et al., 2010). On 
the other hand, an integrative genomic and transcriptomic study of Green et al., (Green et al., 2010) 
identified PDL1 and PDL2 as key targets of the 9p24.1 amplification in PMBCL and cHL, and showed that 
JAK2 can additionally upregulate the expression of the PDL transcripts. The essential role of PDL1/2 in 
the pathogenesis of lymphoma is highlighted by an aberrant expression of these highly 
immunosuppressive proteins in other lymphoma subtypes, including certain aggressive B-cell lymphomas 
and virus-/immunodeficiency-associated malignancies (Chen et al., 2013; Berghoff et al., 2014). By 
expressing the PD-1 ligands, lymphomas, as well as other tumors, can selectively block antitumor 
immune responses (Andorsky et al., 2011). These findings have recently revolutionized the treatment of 
several solid tumors and hematologic malignancies (reviewed by Armand, 2015). Therapeutic blockade of 
PD-1 appeared to be particularly remarkable in cHL (Ansell et al., 2015), prompting further search of 
lymphomas that display similar features and might benefit of this novel form of therapy.  
Most of the 9p24.1 discoveries in lymphoma come from interphase FISH studies, copy number analysis 
and high-throughput sequencing. Therefore, relatively little is known about chromosomal alterations 
underlying these rearrangements. To complete this knowledge and gain more insight into the anatomy of 
the 9p24.1 aberrations, we screened more than 40 leukemia/lymphoma cases with documented 9pter 
abnormalities and approximately 200 cases of unselected cHL by fluorescence in situ hybridization 
(FISH). Here, we report results of detailed molecular cytogenetic investigations of 26 cases of B- and T-
cell malignancies, including cHL, with the cytogenetically and/or FISH-proven 9p24.1 alterations. The 
study demonstrates genetic heterogeneity and complexity of the 9p24.1 alterations in 
leukemia/lymphoma, which seem to predominantly target the PDL locus.   
 
MATERIALS AND METHODS 
Case Selection 
Cases were identified through the Cancer Database of the Center for Human Genetics and Department of 
Pathology, UZ/KU Leuven, Leuven, Belgium. One case (no 1.2) was provided by Dr. Pienkowska-Grela 
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from MSCM Cancer Centre and Institute, Warsaw, Poland. Clinical information was retrieved for all cases 
from the medical records.  
The study was reviewed and approved by the Ethical Committee of the KU Leuven, Leuven, Belgium. All 
samples were collected according to the institutional policies. 
 
Cytogenetics 
Conventional G-banding chromosomal analysis and FISH followed standard protocols. Karyotypes were 
described according to the International System for Human Cytogenetic Nomenclature (ISCN 2013) 
(Shaffer et al., 2013). FISH probes used in this study, as well as their genomic localization, can be found 
in Table S1 and Table S2. Of note, the red-labelled probes included in the JAK2 break-apart  (BA) assay 
cover PDL1 and PDL2 genes located downstream of JAK2 (Figure 1A). Noncommercial probes were 
directly labeled with SpectrumOrange- and SpectrumGreen-dUTP (Abbot Molecular, Ottigne, Belgium) 
using random prime reaction (Invitrogen, Carlsbad, USA). FISH experiments were evaluated using an 
Axioplan 2 fluorescence microscope equipped with a charge-coupled device Axiophot 2 camera (Carl 
Zeiss Microscopy, Jena, Germany) and a MetaSystems Isis imaging system (MetaSystems, Altlussheim, 
Germany). One to 10 abnormal metaphases (and facultatively 200 interphase cells) were evaluated in 
each FISH experiment. Interphase FISH analysis of cHL cases was previously described (Vandenberghe 
et al., 2015). 
 
RNA Extraction and Quantitative Reverse Transcription PCR 
Total RNA was extracted with TRIzol Reagent (Life Technologies, Merelbeke, Belgium), purified with the 
RNeasy Mini Kit (Qiagen, Dorking, United Kingdom) and treated with the Turbo DNA-freeTM kit (Ambion, 
Austin, TX, USA) according to the manufacturer’s instructions. One microgram of the DNase-treated total 
RNA was reverse transcribed into cDNA with random hexamers and SuperScript III (Life Technologies, 
Merelbeke, Belgium).  
Quantitative reverse transcription (QRT)-PCR followed previously described protocols (Lahortiga et al., 
2007), but was carried out on a cDNA template. Primer sequences used in QRT-PCR experiments can be 
found in Table S3. All QRT-PCR experiments were carried out in triplicate and normalized against the 
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HPRT1 reference gene. The fold difference was calculated with the ∆∆Cq method and the expression of a 
mixture of five nonmalignant lymph node samples was set at one. Statistical analysis was done in GraphPad 
with the two-tailed unpaired t-test with a 95% confidence interval. p-values < 0.05 were considered 
statistically significant. 
 
Copy Number Analysis 
Whole-genome high-resolution analysis of four cases (no. 1.1, 1.4, 1.5 and 1.7) was performed with the 
Human Genome CGH Microarray 244A kit (Agilent Technologies, Santa Clara, CA) as previously 
described (Van Roosbroeck et al., 2011), but with some minor modifications. The ADM-2 algorithm was 
chosen to report aberrations for all the samples with a minimum of four probes per aberrant segment. The 
minimum absolute average log ratio was set at 0.22. Two cases (cases 1.6 and 1.9) were analyzed with 
the 2.7 M cytogenetic array from Affymetrix (Santa Clara, CA). The arrays were processed in accordance 
with the manufacturer’s instructions. Raw data were analyzed with the Affymetrix software Chromosome 
Analysis Suite 1.1.0 (ChAS). For annotation information, the Cytogenetic Array Annotation files (Release 
31) provided by Affymetrix, were used. For analysis of copy number alterations, a size of more than 100 
kb and more than 20 markers/copy number alteration were used as thresholds.   
 
RNA Sequencing 
RNA sequencing was performed on the Illumina HiSeq2000 Genome Analyzer using a paired-end format. 
The RNA library preparation was carried out with the TRUseq RNA Sample Preparation Kit (Illumina, San 
Diego, CA) according to the manufacturer’s instructions. Gene fusions were analyzed with the deFuse 
algorithm (McPherson et al., 2011) and ArrayStudio software (www.omicsoft.com). 
 
Immunohistochemistry 
Immunohistochemistry was performed on paraffin-embedded tissue sections with antibodies against 
PDL1 and PDL2 (ProSci Incorporated, Poway, CA). Sections were stained according to the 
manufacturer’s recommendations, and staining results were visualized with the EnVision system (Dako, 
Glostrup, Denmark). Negative, as well as positive controls were included. Images were captured with a 
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Leica DM LB microscope (Leica, Wetzlar, Germany), a Leica PL FLUOTAR objective lens (40x/0.70) and 
a Leica DC200 camera. Images were imported directly into PowerPoint (Microsoft, Redmond, WA) with 
the Leica DC200 camera software (version 2.51). 
 
RESULTS 
Genetic Analysis 
Forty one B-cell leukemia/lymphoma cases with structural 9pter abnormalities were subjected to 
metaphase FISH analysis with a dual-color JAK2 BA assay. An aberrant FISH pattern was identified in 16 
cases, including seven cases with rearranged signals (Table 1) and nine cases with amplified signals 
(Table 2). In the remaining cases, 9p breakpoints occurred either distal (13 cases) or proximal (12 cases) 
to JAK2/PDLs. The cases with breakpoints centromeric to JAK2/PDLs were additionally analyzed with the 
KDM4C BA assay (Table S2) and all showed a normal FISH pattern. 
Table 1 presents seven cases with 9p24.1 rearrangements and two additional cases with apparently 
normal chromosomes 9, but with cryptic aberrations coincidentally detected by routine FISH (cases 1.2 
and 1.9). The cases represent various indolent and aggressive B-cell malignancies, among others CLL in 
Richter transformation (case 1.1) and transformed MALT lymphoma (case 1.8). All 9p24.1 aberrations 
were further characterized by FISH and, if available, by array comparative genomic hybridization (aCGH), 
molecular techniques and RNA-sequencing (case 1.9). The aberrations were heterogeneous and 
included five reciprocal translocations (cases 1.1, 1.2, 1.5, 1.6 and 1.8), two non-reciprocal translocations 
(case 1.3), two insertions (cases 1.4 and 1.7) and one inversion (case 1.9). Two translocations, 
t(4;9)(p14;p24.1) and t(9;14)(p24.1;q32), were found in two cases each (cases 1.6 and 1.8; and cases 1.2 
and 1.3, respectively). To characterize the 9p24.1 breakpoints more in-depth, we applied a set of 31 DNA 
probes covering the 9p21-9pter (~22 Mb) region. The detailed results of metaphase FISH analysis are 
summarized in Table S1. As shown in Figure 1A, all 9p24.1 breakpoints clustered in the 200 kb region 
centromeric to JAK2, harboring PDL1 and PDL2. Intriguingly, in both cases with insertions (cases 1.4 and 
1.7), cryptic microdeletions spanning JAK2 and the neighboring sequences, but not affecting PDL1/2, 
were detected. In case 1.7, the deletion covered approximately 2 Mb region (9:3267306-5325065 bp), as 
estimated by aCGH profiling and confirmed by FISH (Figure S1). The centromeric breakpoint of this 
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deletion occurred approximately 104 kb telomeric to PDL1 and was flanked by RLN1 (retained) and RLN2 
(lost).  
To identify partner genes involved in the 9p24.1 aberrations, all cases were analyzed by metaphase FISH 
with probes selected from the postulated reciprocal region (Table S1). The analysis demonstrated 
involvement of immunoglobulin (IG) genes (IGL/22q11 and IGH/14q32) in cases 1.1-1.3 (Figure 1B) and 
disruption of non-IG sequences in the remaining cases. In cases 1.4 and 1.5, the breakpoints were 
mapped in regions harboring the PHACTR4 (1p34) and EEF1A1 (6q13) genes, respectively. In cases 1.7, 
1.6 and 1.8, the affected genes were not identified, but the breakpoints were narrowed down to the 
3p21.3p24.3 cytoband (3:23600747-45463193 bp) and two overlapping 4p14 regions, 4:39927069-
40657405 bp (N4BP2, RHOH, CHRNA9, RBM47) and 4:39781081-40087915 bp (PDS5A, N4BP2), 
respectively. Notably, both 4p14 breakpoints involved N4BP2, which might be a common target of this 
translocation. Interestingly, case 1.3 had likely unbalanced three-way t(9;13;14)(p24.1;q11;q32) 
associated with loss of der(13)t(13;14)(q11;q32)/5’IGH (green signal). Due to the 9p24.1 break between 
C9orf46 and PDL1, the 9pter region harboring JAK2 was translocated to the rearranged IGH locus at 
der(14), while PDL1/2 were juxtaposed with the gene poor region at 13q11 (centromeric to RP11-
341D18) on der(9). Very intriguing was case 1.9 with biallelic inv(9)(p23p24.1). As shown by aCGH 
(Figure 2A and 2C), the inversion was associated with two microdeletions: (i) at 9p24.1, spanning the 3’ 
end  of JAK2 and the 5’ region of PDL1 (9:5048723-5458818 bp) and leading to the cryptic JAK2-PDL1 
rearrangement, and (ii) at 9p23, likely bordering the centromeric breakpoint of inv(9). As evidenced by 
SNP analysis and confirmed by FISH, the 9p aberrations were biallelic due to uniparental disomy of 9p 
(UPD9p) (Figure 2A-B). Subsequent RNA-sequencing identified the fusion of exon 4 of JAK2 with 
genomic sequences 161 bp upstream of the PDL1 transcript. These findings were validated by RT-PCR 
(Figure 2D). Due to the presence of a premature stop codon, the fusion protein was most likely not 
functional. As insulator sequences located directly upstream of PDL1 were also deleted, the transcription 
machinery could use the JAK2 promoter to aberrantly drive PDL1 mRNA expression.  
FISH analysis was complemented by aCGH performed in six cases (no. 1.1, 1.4, 1.5-1.7, and 1.9). We 
used aCGH data (partially shown) to verify and correct karyotypic abnormalities. Among others, aCGH 
detected cryptic del(9p21) involving CDKN2A/B in cases 1.6, 1.7 (Figure S1) and 1.9, and demonstrated 
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del(6q23)/TNFAIP3 in cases 1.1, 1.5 and 1.6. The latter aberration was present in two additional cases 
not analyzed by aCGH.    
Table 2 presents nine cases with amplified JAK2 BA signals. The patients were diagnosed with PMBCL 
(no 2.1-2.5), PTCL NOS (no 2.6-2.7), ALK-negative ALCL (no. 2.8) and ALK-positive ALCL (no 2.9). Eight 
cases presented with add(9p), which was further specified as a homogeneously staining region (hsr). 
Case 2.4 displayed amplification outside of add(9p). The affected chromosomes showed heterogeneous 
morphology, underlied by a different size and structure of amplicons. For example, the long der(9p) in 
case 2.1 was generated by the 9pter-9pter fusion of two aberrant chromosomes 9 harboring hsr(9p24.1) 
varying in size. It seems that the initial amplicon underwent ‘mirror’ duplication, as deduced from the 
presence of two flanking signals of CDKN2A/9p21 (Figure 1C). The highest level of amplification was 
observed in cases 2.2 and 2.6 (Figure 1C). In case 2.3, the amplified JAK2 BA signals were found on 
der(9) and subclonally, on derivatives of 14, 18 and 22. Three cases (2.2, 2.3 and 2.6) revealed hsr(9p) 
associated with non-reciprocal t(9p24), evidenced by a negative WCP 9 painting of the terminal region 
and loss of the 9p subtelomeric sequences. Because of a low percentage of neoplastic cells in the 
available material, the size of amplicons was not determined by aCGH but provisionally estimated by 
FISH with probes for the 9p-subtelomeric region, KDM4C (6.7 Mb), NFIB (14.08 Mb), CDKN2A/B (21.98 
Mb) and PAX5 (36.83 Mb) (Table S1 and Table S2). The smallest amplified region restricted to 
sequences spanned by the JAK2 BA assay (JAK2<->RANBP6) was found in case 2.2 (Table 2).   
Table 3 presents 8 selected cases of cHL with PDL1/2 alterations detected by FISH in interphase Reed-
Sternberg cells. The majority of these cases were identified during our previous FISH study of cHL (Van 
Roosbroeck et al., 2011). To date, we have analyzed approximately 200 cases of cHL and in four cases 
(no. 3.1-3.4) we have observed loss of the green/JAK2 signal and retain of the red/PDLs signal indicative 
of an unbalanced t(9p24.1). Loss of 9pter was confirmed by FISH with the 9p subtelomeric probe. Lack of 
cytogenetic data prevented identification of partner genes, but involvement of CIITA and IGH in these 
translocations was excluded by FISH. It is worth to note, that the majority of analyzed cHL cases 
displayed copy number gain of the JAK2 BA probes: 78 cases (39%) showed 3-5 extra signals (low copy 
gain) and 40 cases (25%) revealed amplified signals. Remarkably, four of the latter cases (no. 3.5-3.8) 
showed a predominant amplification of the red/PDLs signal (Figure 1D).  
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Expression Analysis 
The expression pattern of five genes potentially targeted by the 9p24.1 aberrations detected in the first 
cohort, JAK2, RLN1, C9orf46, PDL1 and PDL2, was assessed by QRT-PCR in seven available cases. 
The analysis demonstrated upregulation of PDL1 and PDL2 in case 1.4, overexpression of only PDL1 in 
cases 1.7, 1.8 and 1.9, and upregulation of only PDL2 in cases 1.1 and 1.5 (Table 1; Figure 3). No 
candidate gene was overexpressed in case 6. Further mRNA expression analysis of JAK2, PDL1 and 
PDL2 mRNA was performed in three PMBCL cases (no. 2.1, 2.2, 2.4) and single cases of PTCL NOS 
(no. 2.6) and ALK+ ALCL (no.2.9). The analysis detected overexpression of all three genes in cases 2.1 
and 2.4 (the highest expression of PDL1), upregulation of PDL1 and PDL2 in case 2.2, upregulation of 
JAK2 and PDL1 in case 2.6 and overexpression of only PDL1 in case 2.9 (Table 2). Results of QRT-PCR 
analysis performed in two T-cell lymphoma cases with amp(9p24.1) (cases 2.6 and 2.9) are shown in 
Figure 4.  
Finally, available cases were studied by IHC with antisera for PDL1 and PDL2. All cases expressed at 
least one of the proteins analyzed (Table S4, Figure S2). Given, however, that lymphomas frequently 
express PD-1 ligands, the rearrangement-related overexpression of these proteins could not be 
demonstrated. 
 
DISCUSSION 
Our study provides evidence that the structural 9p24.1 aberrations in lymphoid malignancies are 
hallmarked by a common ~200 kb breakpoint region located downstream of JAK2 and harboring PDL1/2. 
These rearrangements seem to target both loci and result in their transcriptional deregulation. As partner 
breakpoints affect (directly or indirectly) various protein-coding genes as well as protein-noncoding 
sequences, a fraction of the 9p24.1 rearrangements may escape detection by high-throughput 
sequencing. Involvement of IG loci, which was documented in t(9;14)(p24.1;q32) and t(9;22)(p24.1;q11), 
is typical for B-cell malignancies. The former translocation was found in two cases diagnosed as primary 
cutaneous DLBCL, leg-type, and B-ALL. Thus far, t(9;14)(p24.1;q32) has not been associated with these 
disease entities, but considering its cryptic nature, the translocation could be overlooked. Basing on the 
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known molecular mechanisms of t(IG) (Willis & Dyer, 2000; Kuppers & Dalla-Favera, 2001), we presume 
that t(9;14)(p24.1;q32) affects JAK2, because this gene, but not PDL1/2, was translocated to der(14) and 
juxtaposed with the 3’IGH enhancer. If so, IGH-JAK2 would be the next JAK2 rearrangement identified in 
B-ALL (Kawamura et al., 2015). This novel JAK2 aberration contrasts with the known JAK2 fusions 
occurring in myeloid neoplasms and acute leukemias, like ETV6-JAK2, BCR-JAK2, PCM1-JAK2  and 
others, which affect the 3’end of the gene and activate the JAK2 tyrosine kinase (Springuel et al., 2015). 
We presume that molecular consequences of t(9;14)(p24.1;q32) are similar to that of amp(9p24.1) and 
inactivated mutations of SOCS1 (inhibitor of JAK2) recurrently occurring in PMBCL (Melzner et al., 2005). 
The latter aberrations lead to elevated transcription of the entire JAK2, followed by phosphorylation of the 
product and subsequent activation of the JAK2/STAT pathway and its targets (e.g. CCND1, OSM, 
BCLxL). Given that JAK2 can additionally upregulate expression of the PDL transcripts (Green et al., 
2010), t(9;14)(p24.1;q32) may also indirectly affect the expression of PD-1 ligands.  
Noteworthy, all the remaining 9p24.1 aberrations, including the IGL-mediated t(9;22)(p24.1;q11), target 
the PDL locus. In contrast to t(9;14)(p24.1;q32), the variant t(9;22)(p24.1;q11) translocates strong 
regulatory sequences of IGL to der(9) and upregulates expression of PDL2, as shown by QRT-PCR. 
Intriguingly, the translocation was detected at the time of Richter transformation of a trisomy 12-positive 
CLL, suggesting its essential role in disease progression. This finding places the PDL2 gene together with 
MYC, BCL3, BMI1 and NOTCH1 on a list of genes implicated in high grade transformation of CLL (Martin-
Subero et al., 2007; De Keersmaecker et al., 2012; Put et al., 2012; Rouhigharabaei et al., 2013). 
Mechanisms of deregulation of the PDL locus by non-IG partner sequences have not been completely 
deciphered. In some cases, transcription of PDL1/2 was probably driven by promoters of partner genes, 
i.e., PHACTR4/1p34, N4BP2/4p14, EEF1A1/6q13 and JAK2/9p24.1, like in the previously reported 
fusions (Steidl et al., 2011; Twa et al., 2014; Twa et al., 2015; Twa & Steidl, 2015). Noteworthy, the 
cryptic JAK2-PDL1 rearrangement was generated by a microdeletion spanning the 3’JAK2-5’PDL1 
region. The effect of this fusion was enhanced by a subsequent UPD9p resulting in duplication of the 
whole 9p. On the other hand, upregulation of the PDL locus by der(9)t(9;13)(p24.1;q13) involving the 
gene poor region at 13q11, might be caused by a position effect and/or loss of negative regulatory 
sequences at 9p24.1. The latter mechanism(s) could be also implicated in both insertions, 
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ins(3;9)(p?24.3;p24.1p?13) and ins(9;1)(p24.1;p34p36), showing deletion of sequences telomeric to the 
9p24.1 breakpoint. Mechanistic significance of the 9pter/JAK2 loss is supported by a recurrent 
occurrence of similar lesions in cHL. Basing on FISH data, we presume that the 9p24.1 rearrangements 
in cHL represent unbalanced translocations targeting the PDL locus and associated with loss of 
9pter/JAK2. Potential partner genes, if any, comprise neither CIITA, known to be involved in the PDL1/2 
fusions in PMBCL (Steidl et al., 2011), nor IGH, engaged in the PDL2-IGV7-81 fusion in one cHL-derived 
cell line (Twa et al., 2014). Further studies of the PDL1/2 rearrangements in cHL are needed to elucidate 
molecular mechanisms underlying these lesions.  
As mentioned above, the most frequent 9p24.1 aberration in lymphoma, particularly in PMBCL and cHL, 
is amplification of the terminal interval spanning JAK2, PDL1, PDL2 and KDM4C. Notably, the  aberration 
is detectable in circulating cell free DNA  from cHL cases (Vandenberghe et al., 2015) and may serve as 
biomarker in non-invasive diagnostic/follow up testing. Also in the present series of selected tumors with 
9pter abnormalities, approximately half of cases (56%) showed amplification of the JAK2/PDLs signals. 
These cases were diagnosed either as PMBCL, or T-cell lymphoma (PTCL NOS, ALK-/ALK+ ALCL). 
Strikingly, none of the PMBCL cases with 9p aberrations revealed PDL1/2 rearrangement, although these 
aberrations seem to mark 20% of PMBCL (Steidl et al., 2011). Of note, we narrowed down the smallest 
amplified 9p24.1 region to the JAK2-PDL1/2-RANBP6  interval, miminizing the role of KDM4C in 
amp(9p24.1)-positive lymphomas (Rui et al., 2010). The amp(9p24.1) was detected in 25% of unselected 
cHL analyzed by interphase FISH, which is in line with previous reports (Joos et al., 2000; Meier et al., 
2009; Green et al., 2010). Although the majory of cHL cases displayed a balanced JAK2/PDLs 
amplification, selective amplification of the PDL locus was observed in several cases. Interestingly, we 
have described a similar amplification peak affecting PDL1/2 in a recently analyzed case of EBV+ 
posttransplant DLBCL, one of two EBV+ DLBCL subtypes showing recurrent amp(9p24.1) (Finalet 
Ferreiro et al., 2015). Altogether, we showed that 9p24.1 aberrations in B-cell malignancies directly or 
indirectly affect the genes coding ligands for PD-1. Previous studies showed that the PDL/PD-1 pathway 
plays an important role in immune evasion of tumor cells. The immunosuppresive ligands expressed on 
tumor cells interact with the co-inhibitory PD-1 on T cells mediating decreased TCR-mediated proliferation 
and cytokine production (Blank & Mackensen, 2007). Functional in vitro and in vivo studies performed on 
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lymphoma cell lines and mouse models demonstarted that PDL1 knockdown inhibits tumor proliferation, 
decreases tumor invasion ability and inhibits cell cycle progression. In addition, downregulation of PDL1 
reverses drug-resistance and increase apoptosis of tumor cell (Li et al., 2012). Based on emerging 
association between the PDL/PD-1 pathway, T-cell exhaustion and tumor progression, novel 
immunotherapies targeting PD-1 has been recently developed. Several clinical trials of the PD-1 blockade 
have already been successfully conducted in hematological malignancies and particularly high response 
rate was obtained in patients with cHL (reviewed by Armand, 2015).  
Summaring, our study confirms the previously published findings of recurrent structural and copy number 
alterations of 9p24.1 in lymphoid malignancies. The rearrangements are cytogenetically and molecularly 
heterogeneous but share the same ‘hot’ breakpoint region downstream of JAK2. They predominantly 
affect the PDL locus and lead to an aberrant expression of PD-1 ligands favoring an immune evasion 
(Blank & Mackensen, 2007; Green et al., 2010). The PDL1/2 rearrangements are not specific but feature 
a broad spectrum of lymphoid malignancies, among others CLL, and contribute in their progression and 
increased aggressiveness.  Amplification of 9p24.1, frequent in PMBCL and cHL, was also detected in T-
cell lymphomas, confirming the previously reported data (present report and Meier et al., 2009). Structural 
aberrations of PDL1/2 and their selective amplification in cHL, which are novel findings, highlight an 
essential role of the PDL locus in the pathogenesis of cHL. As recently shown, the T-cell ’exhaustion” 
which resulted from an aberrant expression of PDL1/2 by neoplastic cells, is reversible with PD-1 
blockade (Ansell et al., 2015). Systematic screening of entities which emerged in our study is warranted 
to identify individuals who may benefit in future from the anti-PD-1 therapy.  
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LEGEND TO THE FIGURES 
Figure 1. Physical map of the 9p24.1 breakpoint cluster and FISH examples of structural and 
numerical 9p24.1 aberrations in lymphoma. (A) Physical map of the 9p24.1 breakpoint cluster of 
approximately 200 kb downstream of JAK2 defined in cases 1.1-1.9. Yellow boxes represent genes, blue 
boxes represent probes, and red and green boxes represent the probes from the JAK2 BA assay. (B) FISH 
analysis of case 1.1 with t(9;22)(p24.1;q11) using the JAK2 BA assay (left panel) and WI2-1621G6-SO/ 
WI2-1844L21-SG (middle panel), and case 1.2 with t(9;14)(p24.1;q32) using LSI IGH (right panel) and 
JAK2 BA probes (inset). (C) Metaphase FISH analysis with probes covering JAK2 (red) and CDKN2A 
(green), and WCP9/SpectrumGreen (inset) in cases 2.1 (left panel), 2.2 (middle panel) and 2.6 with 
amp(9p24). (D) Interphase FISH analysis with the JAK2 BA assay and CEP8/SA (blue) probes in two  cHL 
cases with structural 9p24 aberrations (case 3.2, left panel; case 3.4, middle panel) and amp(9p24) (case  
3.7, right panel).  
 
Figure 2. Complex 9p aberrations in case 1.9 with inv(9).  (A) Upper panel: aCGH profile of the whole 
chromosome 9 showing three microdeletions at 9p24.1 (JAK2-PDL1), 9p23 and 9p21 (CDKN2A/B) 
pointed by red arrows.  Lower panel: SNP data illustrating UPD9p.  Due to the low percentage of 
neoplastic cells (20%) in the analyzed specimen, 9p microdeletions were recognized by the software as 
monoallelic, however, FISH demonstrated biallelic 9p losses and rearrangements (see B). (B) Interphase 
FISH analysis with the JAK2 BA probes (left panel), RP11-125K10-SG/RP11-509D8-SO (middle panel) 
and RP11-140C18-SO/RP11-343D17-SG (right panel) evidencing biallelic 9p24.1 
rearrangements/deletions. (C) aCGH profile of 9p24.1 showing a microdeletion spanning 3’JAK2 and 
5’PDL1/CD274 (marked in green). (D) Schematic representation of the genomic structure of the 
JAK2/PDL1 region and the JAK2-PDL1 rearrangement determined by RNA-sequencing (upper panel) 
and validated by RT-PCR (lower panel). Breakpoint regions are indicated by black arrows.  
 
Figure 3. Expression analysis of JAK2, PDL1 and PDL2 mRNA in cases with structural 9p24.1 
abnormalities. (A) JAK2 is significantly downregulated in 6/7 analyzed cases (marked with **) as compared 
to the average expression in five nonmalignant lymph nodes; (B) PDL1 is significantly upregulated in 4/7 
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analyzed cases (marked with *) as compared to the average expression in five nonmalignant lymph nodes; 
(C) PDL2 is significantly upregulated in 3/7 analyzed cases (marked with *) and significantly downregulated 
in 3/7 cases (marked with **) as compared to the average expression in five non-malignant lymph nodes.  
 
Figure 4. QRT-PCR analysis of JAK2, PDL1 and PDL2 performed in two T-NHL patients with 9p24.1 
amplification. (A) Both JAK2 and PDL1 are significantly upregulated in a case 2.6 (PTCL NOS), as 
compared to the average expression in five non-malignant lymph nodes. (B) Only PDL1 is significantly 
upregulated in a case 2.9 (ALK+ ALCL), as compared to the average expression in five non-malignant 
lymph nodes. JAK2 and PDL2 are significantly downregulated in this patient.   
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Tables 
Table 1: Relevant genetic and clinical data of cases with structural 9p24.1 aberrations 
Case 
n° 
Sex/A
ge Diagnosis Treatment 
Response/ 
Survival 
Sample/ 
Status Cytogenetics
a 
FISH mapped breakpoints QRT-PCR 
9p24.1 Partner chromosome JAK2 RLN1 C9orf46 PDL1 PDL2 
1.1b M/70 CLL in RT 
CHOPx6; 
cerebral RDT; 
palliative care 
PR/died 14 
months after 
diagnosis 
LN/P 47,XY,del(5)(p13.3p15.1),del(6)(q15),t(9;22) (p24.1;q11),+12,der(22)t(1;22)(q11;q13)[3] 
Between WI2-
1621G6 and WI2-
1844L21 
IGL/22q11 (IGL BA and 
CTD-2507C12 split) down down down NL 13.3-fold up 
1.2 M/69 
Primary 
cutaneous 
DLBCL, leg-type 
R-CHOPx8, 
RDT PR TM/D ND .ish t(9;14)(p24.1;q32) 
Between WI2-
1844L21 and WI2-
2110N11 
IGH/14q32 (LSI IGH 
split)  ND ND ND ND ND 
IVACx2 
PR/died 15 
months after 
diagnosis 
TM/P 
43~49,XY,t(1;9)(q21;q34)[5],add(2)(p2?3)[13], 
+3[11],+add(3)(p13)[3],der(5)t(5;10)(q22;q21), 
del(6)(q23)[3], del(8)(p21)[15],t(9;14)(p24.1;q32),-
10,+add(12)(p13)[6],add(15)(q26)[5], 
del(17)(p11.2), +18[13],+2-3mar][cp18] 
Between WI2-
1844L21 and WI2-
2110N11 
IGH/14q32 (LSI IGH 
split)  ND ND ND ND ND 
1.3 M/75 B-ALL ND ND BM/D 
47,XY,der(2)t(2;9)(q13;q31),del(6)(q22),del(8)(p21)
, der(9)t(9;13)(p24.1;q11)t(2;9)(q13;q31), 
+add(9)(q13), -13, der(14)t(9;14)(p24.1;q32),-19, 
+3mar[5] 
Between WI2-
1621G6 and WI2-
1844L21  
IGH/14q32 (LSI IGH 
split; RP11-417P24 and 
11771 separated) 
Unknown/13q11 
(centromeric to RP11-
341D18)  
ND ND ND ND ND 
1.4b M/62 MALT lymphoma 
Splenectomy, 
 
 
R-CHOP x8 
PD, died 77 
months after 
diagnosis 
(DR)  
S/D 
46-47,XY,del(1)(p34p36),t(4;6)(q35;q13),ins(9;1) 
(p24.1;p34p36),+i(9)(p10)[7],der(13)t(X;13)(p11;p1
1), add(14)(q32),add(19)(q13)[cp11] 
Between WI2-
1621G6 and WI2-
1844L21 
PHACTR4/1p34 (RP11-
427O24 and RP4-
669K10 separated) 
NL down NL 11.4-fold up 3.3-fold up 
1.5b M/18 DLBCL R-CHOP like** 
CR/alive 120 
months after 
diagnosis 
LN/P 48,XY,+X,der(4)t(2;4)(p12;p15.1)[9],t(5;16)(q33; p13), t(6;9)(q13;p24),del(6)(q21q23),+8[19] 
Within WI2-
592M24 
Unknown (EEF1A1<-> 
MTO1)/6q13 (RP11-
705N21 and RP11-
772H06 separated) 
down ND ND NL 5.6-fold up 
1.6c M/61 B-LL 
PROMACE-
MOPP; 
palliative care 
at relapse 
CR/relapse/di
ed 84 months 
after 
diagnosis 
(within 1 
month after 
relapse) 
BM/P 
47-48,X,+r(X),Y,del(2)(q12q21),t(4;9)(p14;p24), 
i(6)(p10), del(8)(q11q13),del(9)(p21p21), 
+der(9)t(4;9)(p14;p24)[3], dup(12)(q12q21)[3], 
i(18)(q10)[3],add(19)(q13)[4][cp11] 
Between WI2-
2110N11 and WI2-
2834C19 
?N4BP2/4p14 (RP11-
306G03 and RP11-
666I40 separated) 
down  down down NL down 
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1.7b M/61 MZL 
R-CHOPx6, 
FCRx4 + 
Ritux x2; 
Watch and 
wait 
died 90 
months after 
diagnosis 
from 
secondary 
AML (in 2d 
CR of NHL) 
LN/D 
49,XY,+X,ins(3;9)(p?24.3;p24.1p?13),t(5;9) 
(q13;p21), del(6)(q13q16.3),+7,del(9)(p13p24.2), 
+18[18] 
Between WI2-
424I14 and WI2-
1790I11 
Unknown/3p21.3p24.3  
(RP11-89F18 and 
RP11-111P21 
separated) 
down down NL 1.5-fold up NL 
1.8 F/69 
DLBCL 
(transformed 
MALT 
lymphoma) 
Reduction of 
immune-
suppression, 
Rx4 
PD/died within 
3 months (DR) LN/P 
46,XX,del(3)(q21)[4],t(4;9)(p14;p24),add(10)(q11) 
[6],t(14;18)(q32;q12)[12] 
Between WI2-
1621G6 and WI2-
1844L21 
?N4BP2/4p14 (RP11-
391N20 and RP11-
306G03 separated) 
down ND ND 6.6-fold up down 
1.9c M/49 FL, grade II -IIIa 
Watch and 
wait (7 
months);  
 R-CHOPx8 
and Ritux x2 
CR/alive 64 
months after 
diagnosis 
LN/D  46,XY,t(2;14)(p24;q32),inv(9)(p23q24.1)x2, del(9p21p21)x2,dup(12)(q13.11q21.1)[13] 
Telomeric to WI2-
2110N11  
JAK2/9p24.1 (JAK2 BA 
split) down ND ND 1.4-fold up  down 
Abbreviations: M, male; F, female; CLL, chronic lymphocytic leukemia; RT, Richter transformation; DLBCL, diffuse large B-cell lymphoma; B-ALL, B-cell acute 
lymphoblastic leukemia; MALT, mucosa-associated lymphoid tissue; B-LL, B-cell lymphoblastic lymphoma; MZL, marginal zone lymphoma; FL, follicular 
lymphoma; (R)-CHOP, (rituximab)-cyclophosphamide, doxorubicin, vincristine, prednisone; RDT, radiotherapy; IVAC, ifosfamide, etoposide, high-dose 
cytarabine; ND, not determined; PROMACE-MOPP, prednisone, methotrexate, doxorubicin, cyclophosphamide, etoposide, mechlorethamine, vincristine, 
procarbazine; FCR, fludarabine, cyclophosphamide, rituximab; PR, partial remission; CR, complete remission; PD, progressive disease; LN, lymph node; P, 
progression; TM, tumor (skin); D, diagnosis; BM, bone marrow; S, spleen. 
a Corrected after FISH and aCGH; 9p aberrations appear in bold characters 
b Cases analyzed by aCGH (244k arrays of Agilent) 
c Cases analyzed by SNP arrays (2.7 M arrays of Affymetrix) 
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Table 2: FISH and QRT-PCR analysis of lymphoma cases with 9p24.1 amplification 
Case  Sex/Age Diagnosis  Sample Karyotypea JAK2 BA pattern Range of   amplicon 
QRT-PCR 
JAK2 PDL1 PDL2 
2.1 F/37 PMBCL Med/D 46,XX,add(6)(q27),der(9)(9qter->hsr9p24::hsr9p24->9qter),der(16)t(10;16)(q11;p13)[2],+mar[3]  2 amplicons on der(9) 9pter<->NFIB 4.9-fold up 17.3-fold up 14.7-fold up 
2.2 M/35 PMBCL Med/D 50-51,XY,der(7)t(7;7)(p22;q11)[8],+der(9) add(9)(p24)hsr(9)(p24),add(14)(q32),+2-5 mar,inc[9] 
high-level amplification on 
add(9p24) and 2 signals on mar1 JAK2<->RANBP6 NL 6.8-fold up 5.0-fold up 
2.3 F/27 PMBCL Med/D 
48-50,XX,+X,del(3)(q25),add(3)(q27),der(7)del(7) 
(p15)ins(7;?)(q22;?),+der(9)add(9)(p24)hsr(9)(p24), 
add(14)(q32),add(18)(q22)[2],add(19)(p13),add(22) 
(q13)[2],+2mar[cp10] 
triplicated signals on der(9), 
add(14), add(18) and add(22) 9pter<->NFIB ND ND ND 
2.4 F/31 PMBCL Med/D 50,XX,+X,+5,add(9)(p21),add(14)(q32),del(18)(q21),+2mar[4] amplicons on two markers NA 7.2-fold up 30.6-fold up 10.4-fold up 
2.5 F/46 PMBCL Med/D 
45-50,XX,add(2)(p24)[9],del(3)(q23)[8],del(6) 
(q23q25)[6],+7[9],hsr(9)(p24),+12[7],add(14)(q32)[4],
+del(18)(q21)[3],+20[7],+21[8],+mar1[6],+mar2[2] 
[cp16] 
1 amplicon on hsr(9p24) JAK2<->KMD4C ND ND ND 
2.6 M/62 PTCL NOS/ CLL S/D 
46,XY,add(1)(p36)[8],del(4)(q31q34),del(6) 
(q13q23),der(9)add(9p24)hsr(9)(p24),der(17) 
t(5;17)(q13;p11)[18].ish.del(13)(q14/RB1) (67%) 
 1 amplicon on der(9) (high-level 
amplification)  JAK2<->KMD4C 3.5-fold up 3.4-fold up NL 
2.7 M/38 PTCL NOS BM/P 46,XY,add(5)(q35),hsr(9)(p24),add(21)(p13)[6] 4 amplicons on hsr(9p) JAK2<->NFIB ND ND ND 
2.8 M/40 ALK- ALCL LN/P 
Polyploid (4N),add(1)(p36),add(2)(p24),dup(4)(q?), 
del(5)(p12),del(6)(q23),dup(7)(p22p15),hsr(9)(p24), 
dup(11)(q23q24),add(13)(q34),add(14)(q31),+>10mar
,inc[13] 
1 amplicon on hsr(9p24) JAK2<->KMD4C ND ND ND 
2.9 M/9 ALK+ ALCL LN/D 48,XY,+X,t(2;5)(p23;q35),hsr(9)(p24),del(17)(p11), +19[10] 1 amplicon on hsr(9p24) JAK2<->KMD4C down 2.7-fold up down 
Abbreviations: F, female; M, male; PMBCL, primary mediastinal B-cell lymphoma; PTCL NOS, peripheral T-cell lymphoma, not otherwise specified; CLL, 
chronic lymphocytic leukemia; ALK, anaplastic lymphoma kinase; ALCL, anaplastic large cell lymphoma; Med, mediastinum; S, spleen; BM, bone marrow; LN, 
lymph node; D, diagnosis; P, progression; NL, normal; ND, not determined;  
a9p aberrations appear in bold characters  
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Table 3. FISH analysis of selected Hodgkin lymphoma cases with 9p24.1 aberrations 
Case Diagnosis FISH results Conclusion 
3.1 NSHL 
JAK2 BA/CEP 8 (SA): 3F4R/3B 
5'JAK2 (SG)/PDL1-PDL2 (SO): 3F3R 
CIITA BA: 3-4F 
LSI IGH: 3-4F  
unbalanced t(9p24.1) with bkpt between JAK2 (lost) and PDL1/2 
3.2 NSHL 
JAK2 BA/CEP8 (SA): 3F1R/2B 
5'JAK2 (SG)/PDL1-PDL2 (SO): 3F1G 
CIITA BA: 3F 
IGH BA: 3F 
unbalanced t(9p24.1) with bkpt between JAK2 (lost) and PDL1/2 
3.3 NSHL 
JAK2 BA: 5-7F2R 
5'JAK2 (SG)/PDL1-PDL2 (SO): 3-7F1-2R 
CIITA BA: 3F 
IGH BA: 3F 
unbalanced t(9p24.1) with bkpt between JAK2 (lost) and PDL1/2 
3.4 NSHL 
JAK2 BA/CEP8 (SA): 1F2R/3B 
RP11-509D8 (SG)/RP11-140C18 (SO): 1F 
PDL1/PDL2: 3F 
CIITA BA: 3F 
IGH BA: 3F 
unbalanced t(9p24.1) with bkpt between JAK2 (lost) and PDL1/2 
3.5 NSHL JAK2 BA/CEP8 (SA): 5-8F/3B; 5-7F 1amp(Rpred)/3B 
copy number gain of JAK2 BAP and a suclonal amplification of 
PDL1/2 
3.6 NSHL JAK2 BA:2-4F1amp(Rpred) amplification of 9p24.1 with a predominant gain of PDL1/2 
3.7 HL NOS JAK2 BA/CEP8 (SA): 2F2amp(Rpred)/3-4B;4-7F4-5amp(Rpred)/5-11B amplification of 9p24.1 with a predominant gain of PDL1/2  
3.8 MCHL JAK2 BA/CEP8 (SA):3-5F2GRamp/3B amplification of PDL1/2  
Abbreviations: NSHL, nodular sclerosis Hodgkin lymphoma; HL NOS, Hodgkin lymphoma, not otherwise specified; MCHL, mixed cellularity  Hodgkin 
lymphoma; BA, break apart; SA, spectrum aqua (blue); SG, spectrum green (green); SO, spectrum orange (red); F, fused signal; R4, red signal; G, green 
signal; B, blue signal; amp, amplified signal; Rpred, predominant red signal; bkpt, breakpoint
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Supporting Information 
 
Four Supporting Tables: 
Supplemental Table S1. FISH analyses of B-cell leukemia/lymphoma cases with structural 9p24 
abnormalities. 
Supplemental Table S2. Additional FISH probes 
Supplemental Table S3: Primers used in QRT-PCR and RT-PCR experiments 
Supplemental Table S4: Summary of IHC results 
 
Two Supporting Figures: 
Supporting Figure S1. The 9p24.1 alterations in patient 1.7. (A) Partial karyotype illustrating 
involvement of 9p in two aberrations: ins(3;9)(p?24.3;p24.1p13) (red arrows) and t(5;9)(q13;p21) (blue 
arrows). (B) Examples of FISH with the JAK2 BA assay (left) and WI2-1621G6-SO/WI2-2110N11-SG 
covering PDL1 (right). Note loss of the JAK2/green signal and presence of PDL1 signals on ins(3;9) 
and der(5). (C) aCGH profile of chromosome 9 with two microdeletions detected at 9p21/CDKN2A and 
9p24.1/JAK2. (D) The centromeric breakpoint of the 9p24.1 deletion located between JAK2 and 
PDL1/2 (marked in pink).   
 
Supporting Figure S2. Examples of immunohistochemistry using antisera against PDL1 and PDL2 in 
different lymphoma types harboring structural and numerical 9p24.1 aberrations.  (A‐C) PDL1 is 
expressed in the diffuse neoplastic cells in cases with B‐cell NHL, PMBCL and T‐cell lymphoma. Due to 
the predominance of neoplastic cells,  expression of PDL1 in the accompanying stromal cells cannot 
be evaluated. PDL2 is weakly expressed in the nucleus (and or cytoplasm) of lymphomas, but no 
obvious expression in the stromal cells. (D‐E) In the Hodgkin/Reed‐Sternberg cells (HRS, circled) PDL1 
is strongly expressed in a combined membranous and cytoplasmic pattern. A weaker cytoplasmic 
PDL1 expression is seen in the cytoplasm of the majority of stromal cells. (T: tumor cells; S: stromal 
cells; N: necrosis). Note a strong expression of PDL2 in the cytoplasm (and potentially nucleus) of the 
HRS cells, and weaker, partial cytoplasmic expression in the accompanying stromal cells.  
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Supporting Tables 
Table S1. FISH analyses of B-cell leukemia/lymphoma cases with structural 9p24 abnormalities. 
 
Probes Localization (Mb) 
Case 1.1 Case 1.2 Case 1.3 Case 1.4 Case 1.5 Case 1.6 Case 1.7 Case 1.8 Case 1.9a 
 der(9) der(22) der(9) der(14) der(9) der(14) marb der(9) der(1) der(9) der(6) der(9) der(4) der(9) der(3) der(4) der(9) inv(9) inv(9) 
Chr 9 
9p subtel (1) ND ND ND ND ND ND ND + - ND ND ND ND + - ND ND ND ND 
RP11-307I14 4,721,083-4,831,655 - + - + - + + - - - + - + - - + - + + 
RP11-125K10 4,831,656-5,001,841 - + - + - + + - - - + - + - - + - + + 
WI2-732N1 4,942,238-4,979,354 - + ND ND - + + ND ND ND ND - + - - ND ND ND ND 
WI2-3585O5 4,982,186-5,022,801 - + ND ND - + + ND ND ND ND - + - - ND ND ND ND 
RP11-509D8 5,001,842-5,018,809 - + - + - + + - - - + - + - - + - dim/mv dim/mv 
RP11-154E21 5,017,179-5,144,221 ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND - - 
WI2-2850C2 5,026,385-5,066,923 - + ND ND - + + ND ND ND ND - + - - ND ND ND ND 
WI2-1990K3 5,078,327-5,116,150 - + ND ND - + + ND ND ND ND - + - - ND ND ND ND 
RP11-140C18 5,189,856-5,298,020 - + - + - + + - - - + - + - - + - - - 
WI2-1787H24 5,260,851-5,300,296 ND ND ND ND - + + ND ND ND ND - + - - ND ND ND ND 
WI2-424I14 5,303,176-5,337,602 ND ND ND ND - + + ND ND ND ND - + - - ND ND ND ND 
WI2-1790I14 5,339,442-5,379,592 ND ND ND ND - + + ND ND ND ND - + - + ND ND ND ND 
WI2-1621G6 5,408,033-5,445,949 - + - + - + + - - - + - + - + + - ND ND 
WI2-1844L21 5,445,912-5,485,647 + - - + + - + + - ND ND - + ND ND - + ND ND 
WI2-2110N11 5,470,306-5,509,331 + - + - + - + + - - + - + - + - + +/mv +/mv 
WI2-592M24 5,485,309-5,525,738 ND ND + - ND ND ND + - + (weak) + ND ND ND ND ND ND ND ND 
WI2-2834C19 5,501,423-5,543,929 ND ND + - ND ND ND ND ND + - + - - + - + +/mv +/mv 
WI2-2532G16 5,539,271-5,582,268 ND ND ND ND ND ND ND ND ND + - ND ND - + ND ND ND ND 
RP11-480I24 5,571,006-5,760,432 ND ND + - ND ND ND ND ND ND ND ND ND ND ND - + ND ND 
WI2-1631O2 5,587,603-5,630,859 ND ND ND ND ND ND ND + - + - + - - + ND ND ND ND 
RP11-635N21 5,600,740-5,649,598 + - + - + - + + - + - + - - + - + +/mv +/mv 
RP11-717B10 5,789,062-5,937,516 ND ND + - ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
RP11-218I7 6,005,678-6,072,142 + - + - + - + ND ND ND ND ND ND - + - + ND ND 
RP11-41J05 6,223,060-6,398,690 ND ND + - ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
RP11-247G05 6,363,061-6,508,614 ND ND + - ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
RP11-723E16 6,493,417-6,641,755 ND ND + - ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
RP11-580K10 7,295,409-7,450,317 ND ND + - ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
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RP11-343D17 9,199,596-9,383,041 ND ND + - ND ND ND + - ND ND ND ND - + ND ND + + 
RP11-447H12 9,599,884-9,759,173 ND ND ND ND ND ND ND + - ND ND ND ND - + ND ND ND ND 
LSI CDKN2A Vysis - - ND ND - - - + - + - - - - ND ND ND - - 
Chr 22 
RP11 274M7 23,052,633-23,214,673 - +                  
CTD-2507C12 23,180,066-23,355,157 + +                  
RP11-165G5 23,250,860-23,406,965 + -                  
Chr 14 
LSI IGH BA Vysis   G R - R -             
RP11-417P24 106,196,305-106,364,512   ND ND - + -             
BAC-11771 (2)   ND ND - - -             
Chr 13 
RP11-341D18 18171249-18358106     + - -             
LSI 13 (RB1) Vysis     + - -             
LSI D13S319 Vysis     + - -             
Chr 1 
RP11-49J3 5,945,552-6,043,853        + -           
RP4-635E18 11,065,710-11,176,478        + -           
RP4-745E8 20,607,566-20,686,231        + -           
RP11-132G19 22,051,359-22,224,520        + -           
RP11-509F14 24,626,576-24,634,037        + -           
RP11-304H10 24,727,422-24,908,172        + -           
RP4-633N17 27,360,930-27,479,943        + -           
RP1-144C9 27,702,736-27,780,057        + -           
RP1-159A19 27,857,725-27,981,011        + -           
RP11-427O24 28,057,537-28,202,673        + -           
RP4-669K10 28,829,017-28,962,836        - -           
RP5-893G23 30,541,692-30,628,950        - + (weak)           
RP5-1090M5 37,395,519-37,526,758        - +           
RP5-1034F7 43,575,745-43,650,761        - +           
RP11-184I16 44,150,334-44,249,955        - +           
Chr 6 
RP11-462G2 71,064,771-71,126,997          - +         
RP11-111D8 72,103,204-72,112,282          - +         
RP11-256L9 73,124,203-73,160,829          - +         
RP11-374I18 73,530,353-73,688,036          - +         
RP11-138M05 73,627,395-73,786,422          - +         
RP11-328E03 73,842,334-74,019,788          - +         
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RP11-705N21 74,050,342-74,215,080          - +         
RP11-772H06 74,227,958-74,418,453          + -         
RP11-319B24 74,665,118-74,850,704          + -         
RP11-34L4 75,244,618-75,245,128          + -         
Chr 4 
4p subtel (1)            + -   - +   
LSI IGH/FGFR3 Vysis            ND ND   - +   
RP11-278E22 36,161,294-36,318,582            ND ND   - +   
RP11-36B15 37,515,691-37,674,760            ND ND   - +   
RP11-433F02 39,631,305-39,779,414            + -   - +   
RP11-391N20 39,781,081-39,964,888            + -   - +   
RP11-306G03 39,927,069-40,087,915            + -   + -   
RP11-666I10 40,509,029-40,657,405            - +   + -   
RP11-52K10 40,667,673-40,816,069            ND ND   + -   
RP11-599P02 41,055,576-41,203,917            ND ND   + -   
RP11-764C19 44,347,824-44,533,551            ND ND   + -   
Chr 3 
GS-1186-B18 3psubtel (1)              - +     
RP11-89F18 23,431,548-23,600,747              - 
+ 
/sepd     
RP11-111P21 45,463,193-45,522,973              - 
+ 
/sepd     
Abbreviations: +, present; -, absent; ND, not determined; dim, diminished; sep, separated; mv, moved 
aWe postulate a number of complex genetic events that occurred in this patient, including 
(i) Three microdeletions at 9p24.1, 9p23 and 9p21/CDKN2A/B; the former spans the 3' end of JAK2 and the region flanking the 5' end of PDL1.  
(ii) Inversion of 9p likely associated with 9p23 and 9p24.1 microdeletions; the telomeric breakpoint of the 9p24.1 microdeletion probably occurred between 125K10 and 509D8 (Figure1A). The FISH mapping 
of the centromeric breakpoint of inv(9) is challanging due to a small region which was targeted by the inversion.    
(iii) Uniparental disomy of 9p (9p UPD) covering 9p11.2p24.3, including the region affected by three microdeletions and the JAK2-PDL1 rearrangement. FISH, SNP array and molecular findings in this case 
are illustrated in Figure 1C-E. 
bExtra copy of JAK2 BAP signal was found on a marker chromosome. Array CGH detected a duplication of the 9p24.3-9p24.1 region (1 Mb-7,487,100 Mb) harboring JAK2, PDL1 and PDL2. 
cVysis LSI CDKN2A was applied to validate aCGH/SNP array findings of mono-/bi-allelic deletion of CDKN2A and CDKN2B detected in 5/7 analyzed cases. 
dseparation of RP11-89F18/-111P21 signals indicate that the 9p24.1 region was inserted at 3p21.31p24.3 centromeric to RP11-89F18 and telomeric to RP11-111P21.  
 Breakpoint region 
  Monoallelic deletion 
  Biallelic deletion 
  Duplication 
  Region of insertion 
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Table S2. Additional FISH probes 
Cytoband/gene Probes Genomic localization (hg 19) Reference 
9p24.1 (KMD4C) RP11-151G19 (SO) 6043367-6219086 www.ensembl.org 
  RP11-346G4 (SO) 6270398-6466928 www.ensembl.org 
  RP11-927L8 (SG) 7080501-7274185 www.ensembl.org 
  RP11-958H5 (SG) 7291535-7471568 www.ensembl.org 
9p23/22.3 (NFIB) RP11-1107G7 14148116-14343128 www.ensembl.org 
9p13.2 (PAX5) RP11-243F8 36844939-37033208 www.ensembl.org 
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Table S3: Primers used in QRT-PCR and RT-PCR experiments 
JAK2 ex22-F 5’-AGA ACC TGG TGA AAG TCC CAT ATT-3’ 
JAK2 ex23-R 5’-TGA GGC CAC AGA AAA CTT GCT-3’ 
RLN1 ex2-F 5’-CGA CCC TAC GTG GCA CTG T-3’ 
RLN1 ex2-R 5’-GCA ATA TTT AGC AAG AGA CCT TTT GG-3’ 
C9orf46 ex2-F 5’-GCG TCC TCT AAC ACA TTC AGA CTA CA-3’ 
C9orf46 ex2-3-R 5’-TAT AAA CCC CAT TTT GAC CTC TTT CT-3’ 
PDL1 ex5-F 5’-CCT TGG TGT AGC ACT GAC ATT CA-3’ 
PDL1 ex6-R 5’-TGG ATG CCA CAT TTT TTC ACA-3’ 
HPRT1 ex6-F 5’-TGA CAC TGG CAA AAC AAT GCA-3’ 
HPRT1 ex6-7-R 5’-GGT CCT TTT CAC CAG CAA GCT-3’ 
JAK2-PDL1 Pair 1-F 5'-GGT ATC CAC CCA ACC ATG TCT TCC A-3' 
JAK2-PDL1 Pair 1-R 5'-TGC CGG GCG TTG GAC TTT CC-3' 
JAK2-PDL1 Pair 2-F 5'-TCC ATC TGG GGA GTA TGT TGC AGA-3' 
JAK2-PDL1 Pair 2-R 5'-GCC GGG CGT TGG ACT TTC CT-3' 
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Table S4: Summary of IHC results 
 
Cases 
no. 
Diagnosis Nº of analyzed 
cases 
Nº of cases positive for  
  PDL1a PDL2a 
1.1-1.9 various 6 4 5 
2.1-2.5 PMBCL 5 5 5 
2.6-2.9 T-NHL 3 3 2 
3.1-3.5 cHL 5 4 3 
3.6-3.8 cHL 3 3 3 
 
aExpression of at least one PDL protein was detected in almost all cases analyzed 
 
AB
C
D
CDKN2A/B JAK2 
der(5)
der(3)
der(3)
der(5)
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